Study of Surufatinib with Camrelizumab, Nab-paclitaxel, and Gemcitabine Compared to Nab-paclitaxel Plus Gemcitabine for First Treatment of Metastatic Pancreatic Cancer

What this Trial Is About

Researchers are investigating the effectiveness and safety of a combination treatment using surufatinib with camrelizumab, nab-paclitaxel, and gemcitabine compared to nab-paclitaxel plus gemcitabine alone for patients with metastatic pancreatic cancer. This phase IIIII multicenter trial focuses on patients with stage IV pancreatic cancer who have not received prior first-line systemic treatment for their metastatic disease. The study aims to assess how well these treatments work as initial therapies for this condition. The trial includes three treatment groups one receiving surufatinib 200mg daily plus camrelizumab 200mg by intravenous drip every three weeks on day 1, nab-paclitaxel 125 mgm2 intravenous drip on days 1 and 8, and gemcitabine 1000 mgm2 intravenous drip on days 1 and 8 a second group receiving nab-paclitaxel and gemcitabine alone at the same doses and schedule and a third group receiving surufatinib with nab-paclitaxel and gemcitabine. Treatments are given as first-line therapy for metastatic pancreatic cancer. Participants will be monitored for overall survival from the first dose until withdrawal or death, with follow-up up to about 20 months. Other key measurements include progression-free survival, response rates, duration of response, disease control, and cancer-related quality of life assessments during and after treatment. The study involves regular evaluations and safety monitoring to understand the impact of these therapies on patients health and quality of life.

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer